ArticleAging and disease2025
Epigenetic Regulation of Regulated Cell Death in Aging-Related Diseases: Clinical Perspectives.
Article in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the molecular mechanisms of pyroptosis and its therapeutic development prospects.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intricate crosstalk between epigenetic modification and regulated cell death (RCD) constitutes a pivotal yet underexplored axis in aging and its associated diseases. This Perspective conceptualizes age-related epigenetic reprogramming as a master switch that recalibrates the execution thresholds of diverse RCD pathways-including pyroptosis, ferroptosis, cuproptosis, necroptosis, and autophagy-dependent cell death-across multiple organ systems. We systematically decode how this epigenetic-RCD axis drives the pathophysiology of major aging-related conditions, such as diabetes, neurodegenerative disorders, cardiovascular diseases, and cancer, by synthesizing evidence of how DNA methylation, histone modifications, chromatin remodeling, non-coding RNAs, and RNA methylation intricately govern RCD networks. Building upon this mechanistic framework, the therapeutic potential of targeting this axis is critically examined, highlighting both emerging opportunities and translational challenges for future intervention strategies. Our analysis provides a novel paradigm for understanding aging mechanisms and proposes a roadmap for developing next-generation therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.